| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-130-6-199903160-00004 |
| P698 | PubMed publication ID | 10075615 |
| P2093 | author name string | Weinblatt ME | |
| Garrison L | |||
| Keystone EC | |||
| McDonnell ND | |||
| Schiff MH | |||
| Bulpitt KJ | |||
| Furst DE | |||
| Moreland LW | |||
| Weaver AL | |||
| Mease PJ | |||
| Horwitz DA | |||
| Arkfeld DG | |||
| Baumgartner SW | |||
| Blosch CM | |||
| Fleischmann RM | |||
| Tindall EA | |||
| Burge DJ | |||
| Lange ML | |||
| Ruderman EM | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 478-486 | |
| P577 | publication date | 1999-03-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. | |
| P478 | volume | 130 |
| Q84600096 | Q84600096 |
| Q48089791 | 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. |
| Q35913704 | A Dual Target-directed Agent against Interleukin-6 Receptor and Tumor Necrosis Factor α ameliorates experimental arthritis |
| Q82822413 | A Human Monoclonal Antibody Against Tumor Necrosis Factor-alpha |
| Q28551075 | A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients |
| Q49185981 | A Pilot Dose-Finding Study of Etanercept in Rheumatoid Arthritis |
| Q37445355 | A case of tuberculous arthritis following the use of etanercept |
| Q28188829 | A clinical and economic review of disease-modifying antirheumatic drugs |
| Q50688343 | A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. |
| Q50132265 | A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis |
| Q46390747 | A high molecular weight protein extract of Mastobranchus indicus (Mi-64) having antiarthritic activity in experimental animals |
| Q35638528 | A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs |
| Q45361413 | A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to sever |
| Q35554739 | A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. |
| Q37428436 | A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview |
| Q28250612 | A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis |
| Q35835741 | A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm |
| Q37609399 | A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis |
| Q37604518 | A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy |
| Q53170870 | A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. |
| Q47876324 | A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis |
| Q40372208 | A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate |
| Q37030689 | A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects. |
| Q37091511 | A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis |
| Q36654727 | A role for transcription factor NF-kappaB in autoimmunity: possible interactions of genes, sex, and the immune response |
| Q43957787 | A small molecule ubiquitination inhibitor blocks NF-kappa B-dependent cytokine expression in cells and rats |
| Q43848396 | A soluble mannose receptor immunoadhesin enhances phagocytosis of Pneumocystis carinii by human polymorphonuclear leukocytes in vitro |
| Q41876223 | A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors |
| Q37596520 | A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis |
| Q36741564 | Abatacept in the treatment of rheumatoid arthritis |
| Q36967284 | Abatacept: a novel treatment for rheumatoid arthritis |
| Q40490993 | Active immunization against murine TNFalpha peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. |
| Q57350145 | Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital |
| Q35763157 | Adalimumab in the therapy of uveitis in childhood |
| Q42009131 | Adalimumab in the treatment of arthritis |
| Q41927602 | Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial |
| Q46640059 | Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients |
| Q24234197 | Adverse effects of biologics: a network meta-analysis and Cochrane overview |
| Q38928600 | Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. |
| Q34782898 | American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. |
| Q45381912 | Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice |
| Q31089069 | Anakinra treatment of patients with rheumatoid arthritis |
| Q34124760 | Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs |
| Q34967487 | Ankylosing spondylitis: introductory comments on its diagnosis and treatment |
| Q34216181 | Anti-TNF agents for rheumatoid arthritis |
| Q34450313 | Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases |
| Q24801075 | Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice |
| Q38742606 | Anti-Toxoplasma antibodies in Egyptian rheumatoid arthritis patients |
| Q38826191 | Anti-drug antibodies in Colombian patients with rheumatoid arthritis treated with Enbrel vs Etanar - Preliminary report |
| Q30780014 | Anti-inflammatory potential of alpha-linolenic acid mediated through selective COX inhibition: computational and experimental data |
| Q39715934 | Anti-inflammatory properties of Septilin in lipopolysaccharide activated monocytes and macrophage |
| Q45402264 | Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients |
| Q34967541 | Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience |
| Q24673716 | Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety |
| Q35555781 | Anti-tumour necrosis factor alpha therapy: can we afford it? |
| Q36655144 | Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients |
| Q35554231 | Appropriate and effective management of rheumatoid arthritis |
| Q36408155 | Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities |
| Q38248092 | Are sample sizes of randomized clinical trials in rheumatoid arthritis too large? |
| Q47679436 | Assessing joint destruction in the knees of patients with rheumatoid arthritis by using a semi-automated software for magnetic resonance imaging: therapeutic effect of methotrexate plus etanercept compared with methotrexate monotherapy |
| Q50108689 | Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity |
| Q35555309 | Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha |
| Q24800888 | Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment |
| Q38163603 | B cells participate in tolerance and autoimmunity through cytokine production |
| Q93106999 | Bedside to bench: defining the immunopathogenesis of psoriatic arthritis |
| Q34402267 | Benchmarking and the percentile assessment of RA: adding a new dimension to rheumatic disease measurement |
| Q35549810 | Benchmarking: the five year outcome of rheumatoid arthritis assessed using a pain score, the Health Assessment Questionnaire, and the Short Form-36 (SF-36) in a community and a clinic based sample |
| Q40168997 | Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective |
| Q74469764 | Biliary sepsis in a patient on anti-TNFalpha therapy |
| Q38993250 | Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. |
| Q33203294 | Biologic agents for the treatment of juvenile rheumatoid arthritis: current status |
| Q26471538 | Biologic interventions for fatigue in rheumatoid arthritis |
| Q36195284 | Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). |
| Q34108783 | Biologic therapies in rheumatoid arthritis |
| Q37505012 | Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response |
| Q37087438 | Biologic treatments for systemic rheumatic diseases |
| Q35807230 | Biological agents for rheumatoid arthritis: targeting both physical function and structural damage |
| Q37984565 | Biological agents for the treatment of uveitis |
| Q37390458 | Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. |
| Q37290665 | Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences |
| Q81339952 | Biologicals in rheumatology: Austrian experiences from a rheumatic outpatient clinic |
| Q35893172 | Biologics in combination with nonbiologics: efficacy and safety |
| Q30235341 | Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. |
| Q24185797 | Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis |
| Q86032830 | Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNFα therapy and discontinuation of glucocorticoids |
| Q39131281 | Bone-targeting endogenous secretory receptor for advanced glycation end products rescues rheumatoid arthritis |
| Q47098090 | Breaking the Barrier - Potent Anti-Inflammatory Activity following Efficient Topical Delivery of Etanercept using Thermoresponsive Nanogels. |
| Q38488577 | Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis |
| Q33782282 | Building towards a consensus for the use of tumour necrosis factor blocking agents |
| Q40385305 | CaMKIIδ subtypes differentially regulate infarct formation following ex vivo myocardial ischemia/reperfusion through NF-κB and TNF-α. |
| Q34071308 | Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha |
| Q34091766 | Case management for patients with rheumatoid arthritis |
| Q37345837 | Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials |
| Q37676988 | Certolizumab pegol: a new biologic targeting rheumatoid arthritis |
| Q35573486 | Challenges in assessing costs of rheumatoid arthritis |
| Q38645102 | Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis |
| Q34297049 | Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers |
| Q37895016 | Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years |
| Q82028773 | Chapter 17 Cytokines and pain |
| Q45099938 | Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology |
| Q43607200 | Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies |
| Q36955312 | Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis |
| Q30351543 | Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. |
| Q34897423 | Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register |
| Q35555386 | Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12. |
| Q33809743 | Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis |
| Q38364465 | Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety |
| Q51226661 | Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study. |
| Q37668612 | Clinically validated approaches to the treatment of autoimmune diseases |
| Q35198206 | Co-morbidity in rheumatoid arthritis |
| Q34552451 | Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial |
| Q74209980 | Combination therapy in rheumatoid arthritis |
| Q83966238 | Combination therapy with acitretin for psoriasis |
| Q27694496 | Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analy |
| Q35899264 | Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics? |
| Q28547851 | Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis |
| Q47911250 | Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis |
| Q50779374 | Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. |
| Q42666679 | Comparison of patient satisfaction with two different etanercept delivery systems. A randomised controlled study in patients with rheumatoid arthritis |
| Q83048054 | Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis |
| Q36780936 | Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared? |
| Q57751349 | Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatolo |
| Q92212995 | Conferring extracellular matrix affinity enhances local therapeutic efficacy of anti-TNF-α antibody in a murine model of rheumatoid arthritis |
| Q35873708 | Considerations with the use of biological therapy in the treatment of rheumatoid arthritis |
| Q36961298 | Consumption of hydrolyzable tannins-rich pomegranate extract suppresses inflammation and joint damage in rheumatoid arthritis. |
| Q43048686 | Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden |
| Q34248283 | Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis |
| Q33717053 | Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management. |
| Q37782588 | Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review |
| Q35795354 | Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain. |
| Q45741197 | Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial. |
| Q56904375 | Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion |
| Q57658712 | Cost–effectiveness of tumor necrosis factor-α antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis |
| Q46954910 | Creative trial design in RA: optimizing patient outcomes |
| Q34427742 | Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible |
| Q37763121 | Critical appraisal of pharmacoeconomic studies comparing TNF-alpha antagonists for rheumatoid arthritis treatment |
| Q34279367 | Cross-talk between glucocorticoid receptor and AP-1. |
| Q32060900 | Current management of rheumatoid arthritis |
| Q35210206 | Current treatment of psoriatic arthritis |
| Q46738708 | Current use of glucocorticoids in patients with rheumatoid arthritis in Germany |
| Q43018087 | Cytokine blockers in psoriatic arthritis. |
| Q34190083 | Cytokine modulators in the treatment of sarcoidosis |
| Q35109131 | Cytokine-based immunointervention in the treatment of autoimmune diseases |
| Q44947229 | Cytokines |
| Q34830551 | Cytokines and anti-cytokine biologicals in autoimmunity: present and future |
| Q33974537 | Cytokines in rheumatoid arthritis: trials and tribulations |
| Q35552298 | Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review |
| Q35973747 | Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction |
| Q38648496 | Delayed anti-TNF therapy increases the risk of total knee replacement in patients with severe rheumatoid arthritis. |
| Q92963153 | Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritis |
| Q24816844 | Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study |
| Q73202471 | Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis |
| Q37859679 | Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease |
| Q46873559 | Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis |
| Q36876297 | Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease |
| Q58785143 | Distinguishing rheumatoid arthritis from psoriatic arthritis |
| Q33708846 | Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? |
| Q80094448 | Documenting damage progression in a two-year longitudinal study of rheumatoid arthritis patients with established disease (the DAMAGE study cohort): is there an advantage in the use of magnetic resonance imaging as compared with plain radiography? |
| Q43008546 | Does etanercept induce uveitis? |
| Q38155217 | Drug safety evaluation of certolizumab pegol |
| Q40569388 | Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. |
| Q36010298 | DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing |
| Q38645738 | Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. |
| Q35780354 | Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis |
| Q35746217 | Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis : a therapeutic study using a macrophage-deactivating compound. |
| Q33745949 | Early diagnosis and treatment of rheumatoid arthritis for improved outcomes: focus on etanercept, a new biologic response modifier |
| Q35554321 | Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis |
| Q92737266 | Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials |
| Q33969217 | Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling |
| Q50113586 | Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis |
| Q50155002 | Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database |
| Q51329120 | Effect of tumor necrosis factor-α inhibitors on ambulatory 24-h blood pressure. |
| Q33932391 | Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study |
| Q90334891 | Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts |
| Q64086486 | Effects of bovine tumor necrosis factor alpha decoy receptors on cell death and inflammatory cytokine kinetics: potential for bovine inflammation therapy |
| Q34643251 | Effects of infliximab therapy on gene expression levels of tumor necrosis factor alpha, tristetraprolin, T cell intracellular antigen 1, and Hu antigen R in patients with rheumatoid arthritis |
| Q35550664 | Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. |
| Q51209335 | Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. |
| Q38203622 | Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis |
| Q35554130 | Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed |
| Q33573112 | Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project |
| Q37172815 | Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study |
| Q35638208 | Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study |
| Q38198080 | Efficacy and safety of etanercept in chronic immune-mediated disease |
| Q44692188 | Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial |
| Q35552265 | Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study |
| Q37743492 | Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis |
| Q61453693 | Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis |
| Q58732393 | Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review |
| Q34636263 | Efficacy of anakinra in bone: comparison to other biologics |
| Q36036975 | Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis |
| Q35768542 | Efficacy of etanercept for treating the active rheumatoid arthritis: an updated meta-analysis |
| Q46030933 | Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. |
| Q38993229 | Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis |
| Q36062038 | Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis |
| Q35026464 | Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations |
| Q37739800 | Ellagic acid alleviates adjuvant induced arthritis by modulation of pro- and anti-inflammatory cytokines |
| Q37563441 | Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy |
| Q34071287 | Etanercept (Enbrel): update on therapeutic use |
| Q35638509 | Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis |
| Q62641854 | Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment |
| Q35637985 | Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison |
| Q35020358 | Etanercept biosimilars |
| Q43607191 | Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety |
| Q46916409 | Etanercept for Treating Rheumatoid Arthritis. |
| Q24202751 | Etanercept for the treatment of rheumatoid arthritis |
| Q24248004 | Etanercept for the treatment of rheumatoid arthritis |
| Q58434999 | Etanercept for the treatment of severe childhood psoriasis |
| Q36039222 | Etanercept in arthritis |
| Q34219081 | Etanercept in juvenile rheumatoid arthritis |
| Q34388601 | Etanercept in rheumatoid arthritis |
| Q74265787 | Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial |
| Q52841141 | Etanercept in the treatment of rheumatoid arthritis. |
| Q57330601 | Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis |
| Q42658542 | Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study |
| Q34339649 | Etanercept, a widely used inhibitor of tumor necrosis factor-α (TNF-α), prevents retinal ganglion cell loss in a rat model of glaucoma |
| Q35551908 | Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. |
| Q38045471 | Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment |
| Q35583363 | Etanercept-induced systemic lupus erythematosus |
| Q37292333 | Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis |
| Q35938511 | Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis |
| Q33684274 | Etanercept: a review of its use in rheumatoid arthritis |
| Q36830130 | Etanercept: a review of its use in the management of rheumatoid arthritis |
| Q37754607 | Etanercept: an introduction |
| Q34991484 | Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis |
| Q34502007 | Etanercept: effective in the management of hidradenitis suppurativa |
| Q37954714 | Etanercept: efficacy and safety for approved indications |
| Q36847326 | Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis |
| Q33782355 | Etanercept: therapeutic use in patients with rheumatoid arthritis |
| Q35190112 | Evaluation and management of psoriatic arthritis: the role of biologic therapy |
| Q35638560 | Evaluation of a modified ACR20 scoring system in patients with rheumatoid arthritis receiving treatment with etanercept |
| Q44384544 | Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly |
| Q24291472 | Evidence of IL-18 as a novel angiogenic mediator |
| Q52925161 | Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. |
| Q36823811 | Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis |
| Q34587424 | Experience with etanercept in an academic medical center: are infection rates increased? |
| Q74256124 | Extraintestinal Complications of Inflammatory Bowel Disease |
| Q58003948 | Factors Associated with Severe Skin Infections in Patients Treated with Biologic Therapies for Inflammatory Rheumatic Diseases |
| Q37761399 | Fish oil and rheumatoid arthritis: past, present and future |
| Q35605643 | Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity |
| Q36475642 | Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis |
| Q39321571 | GADD45γ regulates TNF-α and IL-6 synthesis in THP-1 cells |
| Q42222701 | Gene therapy with an improved doxycycline-regulated plasmid encoding a tumour necrosis factor-alpha inhibitor in experimental arthritis |
| Q48064243 | Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. |
| Q41922931 | Generalization and extrapolation of treatment effects from clinical studies in rheumatoid arthritis |
| Q34981859 | Genetic influences on rheumatoid arthritis in African Americans |
| Q34034360 | Geropharmacology for the rheumatologist |
| Q35552156 | Glucocorticoids in the treatment of early and late RA |
| Q35941069 | Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action |
| Q34609376 | Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial |
| Q57752112 | Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study |
| Q34601527 | Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study |
| Q44911715 | Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function fin |
| Q33973884 | Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. |
| Q56212157 | Guidelines for the management of rheumatoid arthritis: 2002 Update |
| Q36457930 | Guidelines for the proper use of etanercept in Japan |
| Q37498849 | Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis |
| Q37678277 | Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan. |
| Q92528170 | Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders |
| Q41721385 | Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo |
| Q46534048 | Hierarchical network meta-analysis models to address sparsity of events and differing treatment classifications with regard to adverse outcomes |
| Q44083454 | How should impaired morning function in rheumatoid arthritis be treated? |
| Q34227694 | Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease |
| Q36292663 | IKK{beta} as a target for treatment of inflammation induced bone loss |
| Q34114520 | Immune function |
| Q34511936 | Immune-based therapies: a review of clinical endpoints used in trials of selected immunologic agents |
| Q36778450 | Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution |
| Q38080683 | Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis |
| Q79151701 | Immunogenicity, efficacy and adverse events of adalimumab in RA patients |
| Q37668179 | Immunotherapy of rheumatoid arthritis targeting inflammatory cytokines and autoreactive T cells |
| Q38129036 | Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis. |
| Q34109394 | Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data |
| Q35630063 | Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden |
| Q46230245 | Impact of managed care on the use of biologic agents for rheumatoid arthritis |
| Q34538213 | Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis |
| Q35097253 | Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life |
| Q30594247 | Incorporating data from various trial designs into a mixed treatment comparison model |
| Q92616949 | Increased Nonexudative Age-Related Macular Degeneration Diagnosis Among Medicare Beneficiaries With Rheumatoid Arthritis |
| Q37129859 | Indian herbal medicines: possible potent therapeutic agents for rheumatoid arthritis |
| Q37236822 | Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials |
| Q35084908 | Infection complications associated with the use of biologic agents |
| Q80488259 | Infection of an urachal cyst during etanercept therapy in juvenile idiopathic arthritis |
| Q28083759 | Inflammation induced loss of skeletal muscle |
| Q36389123 | Inflammatory arthritides of the spine: surgical versus nonsurgical treatment |
| Q33885648 | Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group |
| Q44016935 | Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study |
| Q44477953 | Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease |
| Q80541644 | Infliximab in rheumatoid arthritis |
| Q34292153 | Infliximab treatment for Crohn's disease |
| Q35555743 | Infliximab treatment reduces complement activation in patients with rheumatoid arthritis |
| Q34219694 | Infliximab, an anti-TNF-alpha agent, improves left atrial abnormalities in patients with rheumatoid arthritis: preliminary results |
| Q49110928 | Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis |
| Q35632732 | Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis |
| Q36573901 | InforMatrix: treatment of rheumatoid arthritis using biologicals |
| Q36959443 | Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics |
| Q85049421 | Integrated Population Pharmacokinetics of Etanercept in Healthy Subjects and in Patients With Rheumatoid Arthritis Ankylosing Spondylitis |
| Q24793971 | Interferon-beta for treatment of rheumatoid arthritis? |
| Q34343286 | Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy |
| Q37928726 | Interpreting clinical trial results for moderate-to-severe rheumatoid arthritis: practical applications for rheumatology healthcare providers |
| Q34553531 | Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study |
| Q45805620 | Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort. |
| Q38472252 | Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis |
| Q34626968 | Juvenile rheumatoid arthritis: therapeutic perspectives |
| Q35826170 | Leflunomide in active rheumatoid arthritis: a prospective study in daily practice |
| Q55540665 | Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. |
| Q43061691 | Leflunomide in the treatment of rheumatoid arthritis |
| Q34240771 | Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis |
| Q35553371 | Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis |
| Q37258347 | Limits of add-on trials: antirheumatic drugs |
| Q34153033 | Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis |
| Q35551481 | Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. |
| Q35636875 | Long term safety of etanercept in elderly subjects with rheumatic diseases |
| Q36761836 | Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study |
| Q50114940 | Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies |
| Q34607794 | Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension |
| Q33245010 | Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis |
| Q44581266 | Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up |
| Q36480668 | Macrophage migration inhibitory factor and glucocorticoid sensitivity. |
| Q26750562 | Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis |
| Q53828883 | Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. |
| Q34764172 | Management of inflammatory arthritis around the elbow |
| Q40151089 | Management of the patient with severe refractory rheumatoid arthritis: are the newer treatment options worth considering? |
| Q33754764 | Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis. |
| Q43640818 | Mechanism of action of disease modifying anti-rheumatic agent, gold sodium thiomalate (GSTM). |
| Q37536373 | Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). |
| Q36067667 | Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors |
| Q33793215 | Medical management of children with juvenile rheumatoid arthritis |
| Q38054991 | Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis |
| Q36818355 | Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration |
| Q51943185 | Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. |
| Q26824970 | Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors |
| Q34236658 | Monoclonal antibody therapy |
| Q35909297 | Monoclonal antibody therapy in lymphoid leukemias |
| Q57074607 | NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis |
| Q38879533 | Neuropharmacologic Approaches to Restore the Brain's Microenvironment. |
| Q35541936 | New Perspectives and Emerging Therapies for Immune-mediated Inflammatory Disorders |
| Q37358229 | New and emerging therapies for the treatment of rheumatoid arthritis. |
| Q44518215 | New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval |
| Q34027901 | New biologic agents: a critical appraisal |
| Q33884532 | New medications for use in patients with rheumatoid arthritis |
| Q35210204 | New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate |
| Q36088346 | New therapies for rheumatoid arthritis |
| Q33801264 | New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders |
| Q34699641 | No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register |
| Q34108901 | Non-HIV retroviral associations with rheumatic disease |
| Q35918691 | Novel Human Three-Domain Antibody Fragments Against sTNFα as Well as tmTNFα with High Affinity Generated by the Combination of Ribosome Display and E. coli Expression System |
| Q37650386 | Novel TNF antagonists for the treatment of rheumatoid arthritis |
| Q81096216 | Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Q51051039 | Novel tumor necrosis factor alpha-regulated genes in rheumatoid arthritis. |
| Q34096275 | Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases |
| Q30896344 | Number needed to treat (NNT): implication in rheumatology clinical practice |
| Q45324145 | Off-target activity of TNF-alpha inhibitors characterized by protein biochips |
| Q51345030 | Office-based arthroscopic synovectomy of the wrist in rheumatoid arthritis. |
| Q51051064 | Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. |
| Q46786771 | Optic neuritis with concurrent etanercept and isoniazid therapy. |
| Q38993316 | Optimal dose of etanercept in the treatment of rheumatoid arthritis |
| Q38264653 | Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase |
| Q57751326 | Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study |
| Q35553607 | Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis |
| Q33782360 | PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases |
| Q34156390 | Pain management in older adults: prevention and treatment |
| Q43445519 | Parapharyngeal abscess in a patient receiving etanercept |
| Q34637331 | Pathogenesis of bone lesions in rheumatoid arthritis |
| Q35636868 | Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial |
| Q24791246 | Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study |
| Q35953238 | Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis |
| Q46598057 | Pharmaceutical care of patients with rheumatoid and psoriatic arthritis receiving etanercept |
| Q60935710 | Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment |
| Q58779789 | Pharmacoeconomic evaluation of treatment effectiveness with selected biologic treatment in rheumatoid arthritis therapy |
| Q35131199 | Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis |
| Q35198225 | Pharmacological treatment of established rheumatoid arthritis |
| Q30699616 | Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologicals in Germany : real-life clinical practice data |
| Q24793076 | Phenotypic characteristics of human monocytes undergoing transendothelial migration |
| Q73086679 | Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment |
| Q81346942 | Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis |
| Q44566796 | Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept |
| Q35154359 | Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis |
| Q30863549 | Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases |
| Q45359154 | Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis |
| Q64272847 | Precision drug repurposing via convergent eQTL-based molecules and pathway targeting independent disease-associated polymorphisms |
| Q42956746 | Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate |
| Q35761447 | Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease |
| Q36160421 | Prefilled certolizumab pegol (Cimzia(®)) syringes for self-use in the treatment of rheumatoid arthritis |
| Q35555622 | Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum |
| Q73245623 | Psoriasis |
| Q36040084 | Psoriatic arthritis treatment: biological response modifiers |
| Q35902691 | Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist. |
| Q37221707 | Psychological adjustment to chronic disease |
| Q80969477 | Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy |
| Q35780344 | Pursuit of optimal outcomes in rheumatoid arthritis |
| Q37314019 | Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: a systematic review |
| Q40401339 | Quality of life and costs for different treatment strategies for rheumatoid arthritis |
| Q80397866 | Quality-of-Life Measurements in Juvenile Rheumatoid Arthritis Patients Treated with Etanercept |
| Q31935385 | Radiography of rheumatoid arthritis in the time of increasing drug effectiveness |
| Q37397646 | Randomized controlled trial design in rheumatoid arthritis: the past decade |
| Q49049736 | Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy |
| Q58853219 | Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab |
| Q37020532 | Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. |
| Q47861250 | Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA. |
| Q36732112 | Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register |
| Q46379201 | Respiratory complications of new treatments for rheumatoid arthritis |
| Q49132489 | Response of TNF-hyporesponsive SPRET/Ei mice in models of inflammatory disorders |
| Q24800647 | Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis |
| Q33667897 | Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population |
| Q33904308 | Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease |
| Q58563236 | Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis |
| Q74541001 | Rheumatoid arthritis |
| Q91359259 | Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis |
| Q36160669 | Rheumatoid arthritis: an overview of new and emerging therapies |
| Q55025616 | Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. |
| Q37120627 | Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists |
| Q53413570 | Rheumatology, geriatrics, and a way forward. |
| Q33315300 | Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials |
| Q36760300 | Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis |
| Q38234629 | Rituximab and tocilizumab for the treatment of rheumatoid arthritis |
| Q52888818 | S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. |
| Q38827889 | Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance |
| Q35999139 | Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis |
| Q34595156 | Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept |
| Q35194346 | Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis |
| Q53454276 | Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis |
| Q44747942 | Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years |
| Q89718070 | Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study |
| Q33644805 | Safety of etanercept in elderly subjects with rheumatoid arthritis |
| Q24675209 | Safety of extended treatment with anakinra in patients with rheumatoid arthritis |
| Q53878659 | Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis. |
| Q35638718 | Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial |
| Q35937819 | Serious infections associated with anticytokine therapies in the rheumatic diseases |
| Q42279214 | Serum cytokine concentrations in a patient with rheumatoid arthritis on etanercept therapy who subsequently developed pneumocystis pneumonia: a case report |
| Q36028645 | Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. |
| Q40374825 | Short-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis |
| Q37500219 | Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for |
| Q46878568 | Sjögren syndrome in a child: favorable response of the arthritis to TNFalpha blockade |
| Q34779777 | Soluble cytokine receptors in biological therapy |
| Q34074749 | Soluble cytokine receptors: novel immunotherapeutic agents |
| Q43779887 | Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha |
| Q35714438 | Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. |
| Q64258617 | Sources of Pathogenic Nucleic Acids in Systemic Lupus Erythematosus |
| Q51176752 | Stakeholder Satisfaction with the Australian Rheumatology Association Database (ARAD). |
| Q44284924 | Structure-activity relationships of 6-fluoroquinazolines: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation |
| Q34770459 | Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis |
| Q33402894 | Suppression of complete Freund's adjuvant-induced adjuvant arthritis by cobratoxin |
| Q34967884 | Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation |
| Q35579309 | Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. |
| Q35554952 | Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks |
| Q33336433 | Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes |
| Q41504272 | Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis |
| Q34506884 | Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). |
| Q21134808 | Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis |
| Q34523450 | Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70 |
| Q36359571 | T cell targeted immunotherapy for autoimmune disease |
| Q36452687 | T-cell activation via CD26 and caveolin-1 in rheumatoid synovium |
| Q43837384 | TIA-1 regulates the production of tumor necrosis factor alpha in macrophages, but not in lymphocytes |
| Q37758202 | TNF receptor 2 pathway: drug target for autoimmune diseases |
| Q42592010 | TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations |
| Q93018229 | TNF-α antagonist attenuates systemic lipopolysaccharide-induced brain white matter injury in neonatal rats |
| Q36536861 | TNFalpha blockade in human diseases: an overview of efficacy and safety |
| Q36536886 | TNFalpha blockade in human diseases: mechanisms and future directions |
| Q35554338 | TNFalpha therapy in psoriatic arthritis and psoriasis |
| Q36349618 | Tacrolimus in rheumatoid arthritis |
| Q39393744 | Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults |
| Q34436456 | Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases |
| Q37208475 | The Burden of Rheumatic Diseases: An Analysis of an Italian Administrative Database |
| Q36801049 | The Development of Novel Therapies for Rheumatoid Arthritis |
| Q43913784 | The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation |
| Q35864869 | The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis |
| Q35556360 | The biology of TNF blockade |
| Q37044639 | The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments |
| Q53860668 | The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis. |
| Q37387224 | The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis |
| Q60017517 | The current state of the art for biological therapies and new small molecules in inflammatory bowel disease |
| Q35636615 | The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis |
| Q37760938 | The efficacy and safety of golimumab in the treatment of arthritis |
| Q36204163 | The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice |
| Q64229650 | The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports |
| Q34071304 | The final pathogenetic steps in focal bone erosions in rheumatoid arthritis |
| Q34108788 | The genetics of rheumatoid arthritis: influences on susceptibility, severity, and treatment response |
| Q34607576 | The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation |
| Q79141725 | The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis |
| Q33311301 | The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review |
| Q52654900 | The role of lymphotoxin-α in rheumatoid arthritis. |
| Q35127430 | The role of the interleukin‐6 family of cytokines in inflammatory arthritis and bone turnover |
| Q34027484 | The role of tumor necrosis factor alpha in the pathophysiology of congestive heart failure |
| Q38992643 | The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar. |
| Q35859217 | The treatment of rheumatoid arthritis |
| Q34108762 | The treatment of rheumatoid arthritis: a review of recent clinical trials |
| Q35688168 | The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview |
| Q36916918 | The use of TNF-alpha blocking agents in rheumatoid arthritis: an update |
| Q30576366 | The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis |
| Q38132555 | The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. |
| Q33976382 | Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial |
| Q39350335 | Therapeutic effects of a novel tylophorine analog, NK-007, on collagen-induced arthritis through suppressing tumor necrosis factor α production and Th17 cell differentiation |
| Q37552947 | Therapeutic options for rheumatoid arthritis |
| Q34375258 | Tissue specific CD4+ T cell priming determines the requirement for interleukin-23 in experimental arthritis |
| Q37717012 | Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis |
| Q53614685 | Toll-like receptors: a new target in rheumatoid arthritis? |
| Q34567932 | Treating rheumatoid arthritis with new disease modifying drugs |
| Q42775955 | Treating rheumatoid arthritis with tumour necrosis factor alpha blockade |
| Q35556040 | Treatment continuation in patients receiving biological agents or conventional DMARD therapy |
| Q53983532 | Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. |
| Q36633460 | Treatment of inflammatory dermatoses by tumour necrosis factor antagonists |
| Q46873586 | Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study |
| Q56060521 | Treatment of rheumatoid arthritis |
| Q44930010 | Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial |
| Q34585883 | Treatment of rheumatoid arthritis: etanercept a recent advance |
| Q33946522 | Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab |
| Q47132835 | Treatment with Biologicals in Rheumatoid Arthritis: An Overview. |
| Q24800661 | Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis |
| Q35554567 | Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies |
| Q37302417 | Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis |
| Q33328963 | Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety |
| Q36984088 | Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort |
| Q37008829 | Tumor necrosis factor as a therapeutic target of rheumatologic disease |
| Q77924189 | Tumor necrosis factor microsatellite alleles in patients with rheumatoid arthritis in Taiwan |
| Q34568701 | Tumor necrosis factor or tumor promoting factor? |
| Q46192977 | Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials |
| Q34276023 | Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis |
| Q35582517 | Tumour Necrosis Factor in Sarcoidosis and its Potential for Targeted Therapy |
| Q50851551 | Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. |
| Q37726193 | Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis |
| Q37580905 | Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety |
| Q35967186 | Two inhibitors of DNA-synthesis lead to inhibition of cytokine production via a different mechanism |
| Q28674280 | Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis |
| Q38071693 | Update on biologicals for treatment of juvenile idiopathic arthritis |
| Q37081486 | Update on the natural history and systemic treatment of psoriasis |
| Q37290628 | Update on the use of etanercept across a spectrum of rheumatoid disorders |
| Q35638252 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. |
| Q35553451 | Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). |
| Q34962946 | Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). |
| Q35579352 | Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. |
| Q35579517 | Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 |
| Q34560553 | Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001) |
| Q82299257 | Urticaria and angiedema-like skin reactions in a patient treated with adalimumab |
| Q37000165 | Use of biologics in rheumatoid arthritis: current and emerging paradigms of care |
| Q57995927 | Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis |
| Q51866003 | Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. |
| Q44599587 | Value of anti-TNF-alpha molecules in inflammatory and infectious diseases |
| Q35200354 | Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. |
| Q35954625 | What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. |
| Q35579347 | Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues |
| Q53855814 | [Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies]. |
| Q79192816 | [Effectiveness and safety of adalimumab and etanercept for rheumatoid arthritis in a third-level hospital] |
| Q79802311 | [Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab] |
| Q81772569 | [Four-year observation of etanercept therapy for rheumatoid arthritis in a single German center] |
| Q84600797 | [Infections in Patients With Rheumatoid Arthritis Undergoing Anti-TNFα Drug Therapy] |
| Q53936758 | [Inhibitors of TNFalpha]. |
| Q52938817 | [Prescription of glucocorticoids by rheumatologists in patients with rheumatoid arthritis in Germany]. |
| Q74042917 | [Systematic review of clinical trials on the treatment of rheumatoid arthritis with tumour necrosis factor alpha inhibitors] |
| Q28564602 | rSj16, a recombinant protein of Schistosoma japonicum-derived molecule, reduces severity of the complete Freund's adjuvant-induced adjuvant arthritis in rats' model |
Search more.